FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute ...
The FDA approved OCREVUS ZUNOVO™, a twice-a-year subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options. This approval is supported by a decade of safety and efficacy data from Ocrevus® IV, with over 350,000 people treated globally. OCREVUS ZUNOVO™ provides flexibility in treatment administration, potentially expanding access to those without IV infrastructure.
Reference News
The FDA approved OCREVUS ZUNOVO™, a twice-a-year subcutaneous injection for relapsing and primary progressive multiple sclerosis, offering more treatment options. This approval is supported by a decade of safety and efficacy data from Ocrevus® IV, with over 350,000 people treated globally. OCREVUS ZUNOVO™ provides flexibility in treatment administration, potentially expanding access to those without IV infrastructure.